Development of a tetravalent anti-GPA33/anti-CD3 bispecific antibody for colorectal cancers Journal Article


Authors: Wu, Z.; Guo, H. F.; Xu, H.; Cheung, N. K. V.
Article Title: Development of a tetravalent anti-GPA33/anti-CD3 bispecific antibody for colorectal cancers
Abstract: Despite progress in the treatment of colorectal cancer, curing metastatic colorectal cancer remains a major unmet medical need worldwide. Here, we describe a T-cell-engaging bispecific antibody (T-BsAb) to redirect polyclonal cytotoxic T cells to eradicate colorectal cancer. A33, a murine antibody specific for GPA33, was humanized to huA33 and reformatted to huA33-BsAb, based on a novel IgG(L)-scFv platform by linking the anti-CD3 huOKT3 scFv to the carboxyl end of the light chain. This T-BsAb was stably expressed in CHO cells and purified as a stable monomer by HPLC, retaining immunoreactivity by FACS through 30 days of incubation at 37C. In vitro, it induced activation and expansion of unstimulated T cells and elicited potent T-cell-dependent cell-mediated cytotoxicity against colon and gastric cancer cells in an antigen-specific manner. In vivo, huA33-BsAb inhibited the colon and gastric cancer xenografts, in both subcutaneous and intraperitoneal tumor models. More importantly, both microsatellite instable and microsatellite stable colorectal cancer were effectively eliminated by huA33-BsAb. These preclinical results provide further support for the use of IgG(L)-scFv platform to build BsAb, and especially one targeting GPA33 for colorectal cancer. These preclinical results also support further development of huA33-BsAb as a potential immunotherapeutic. © 2018 American Association for Cancer Research.
Journal Title: Molecular Cancer Therapeutics
Volume: 17
Issue: 10
ISSN: 1535-7163
Publisher: American Association for Cancer Research  
Date Published: 2018-10-01
Start Page: 2164
End Page: 2175
Language: English
DOI: 10.1158/1535-7163.mct-18-0026
PUBMED: 30082472
PROVIDER: scopus
PMCID: PMC6168351
DOI/URL:
Notes: Article -- Export Date: 1 November 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Nai-Kong Cheung
    648 Cheung
  2. Hong Xu
    53 Xu
  3. Hong-Fen Guo
    73 Guo
  4. Zhihao Wu
    6 Wu